Personal CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
Christopher M. Hall, Chief Executive Officer of It’s personal (NASDAQ:PSNL)disclosed the direct exercise and immediate sale of 100,000 shares of Common Stock, valued at approximately $1.10 million, in a transaction reported on May 29, 2026. SEC Form 4 filing
Transaction summary
|
Metric |
Price |
|---|---|
|
Shares for sale (direct) |
100,000 |
|
Transaction amount |
$1.1 million |
|
Post-trade shares (direct) |
235,986 |
|
Post-transaction value (direct ownership) |
~$2.6 million |
Transaction and post-transaction prices are based on the SEC Form 4 weighted average of the reported price ($11.02).
Key questions
-
What does the size of this purchase indicate about Hall’s remaining direct ownership?
After selling 100,000 shares (29.76% of direct holdings), Hall continues to own 235,986 direct shares of Common Stock, representing a remaining direct equity position of approximately $2.6 million as of May 29, 2026. -
How does the deal relate to the strength of the available Hall option?
The shares sold stem from the exercise of the option, and Hall retains 300,000 options outstanding, highlighting the remaining capacity to acquire additional Common Stock through future exercises. -
Was this activity a trend or a sign of change in marketing?
Compared to previous activities (trade sizes only sold from 20,459 shares to 29,612 shares), this action and sale is materially larger, but the increase is explained by the amount available in the option, instead of the increase in the option of the situation pattern. -
Does Hall retain indirect or other class items following this purchase?
No shares are held indirectly; However, Hall retains 300,000 options, which are convertible into Common Stock, ensuring beneficial continuation of stock ownership.
Company overview
|
Metric |
Price |
|---|---|
|
Price (as of market close on May 29, 2026) |
$11.40 |
|
Market capitalization |
$1.19 billion |
|
Revenue (TTM) |
$64.52 million |
Company summary
-
Personalis provides genomic sequencing and data analysis services for cancer research and therapeutic development, including the NEXT Platform, ImmunoID Next, NeXT Liquid Biopsy, NeXT Personal, and related products.
-
It generates revenue primarily through service contracts with biopharmaceutical companies, research institutions, and government agencies for large-scale genetic research and clinical applications.
-
The company serves biopharmaceutical firms, universities, non-profit organizations, and government agencies focused on oncology and precision medicine.
Personal is a cancer genomics company focused on advanced sequencing and analysis platforms that support oncology research and the development of targeted therapies.
